Growth hormone response to clonidine in anovulatory infertile women resistant to clomiphene citrate stimulation
|
|
- Katrina Dalton
- 6 years ago
- Views:
Transcription
1 FERTILITY AND STERILITY VOL. 73, NO. 1, JANUARY 2000 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Growth hormone response to clonidine in anovulatory infertile women resistant to clomiphene citrate stimulation Plinio Rossato, M.D.,* Francesco Minuto, M.D., Simona Garrone, M.D., and Nicola Ragni, M.D. Ospedale Evangelico Internazionale, and University of Genova, Genova, Italy Objective: To evaluate the GH response to the clonidine test in a group of infertile women and to determine their ovulatory response to clomiphene citrate (CC) stimulation. Design: Prospective study. Setting: Reproductive endocrinology unit. Patient(s): Thirty-three anovulatory infertile women (age range, years) and 9 healthy controls with normal ovulation. Intervention(s): In the early follicular phase, 0.3 mg of clonidine was administered between 8:30 and 9:00 A.M. and blood samples were collected for 120 minutes thereafter for measurement of serum GH levels. Plasma levels of insulin and glucose were measured after a 75-g glucose load, and CC was given at a dosage of mg/d for ovulation induction. Main Outcome Measure(s): Serum concentrations of GH, insulin-like growth factor I, insulin, and insulinlike growth factor binding protein-1. Result(s): On the basis of their ovulatory response to CC, 15 patients were considered nonresponsive (group 1) and 18 patients were considered responsive (group 2). Baseline levels of GH, insulin-like growth factor I, and insulin-like growth factor binding protein-1 were similar in the two groups of patients and the controls. The GH response to clonidine was significantly greater in group 2 and in the controls than in group 1. Concentrations of insulin and glucose after the glucose load were not different among the three groups. Conclusion(s): Women who were resistant to CC had a reduced GH response to clonidine. These data suggest that adequate GH secretory capacity is important for CC action. (Fertil Steril 2000;73: by American Society for Reproductive Medicine.) Key Words: GH, clomiphene citrate, clonidine, anovulatory infertility Received March 23, 1999; revised and accepted August 2, Reprint requests: Plinio Rossato, M.D., Ospedale Evangelico Internazionale, Salita Superiore San Rocchino 31/A, Genova, Italy (FAX: ). * Division of Obstetrics and Gynecology, Ospedale Evangelico Internazionale. Department of Endocrinology and Metabolism, University of Genova. Department of Obstetrics and Gynecology, University of Genova /99/$20.00 PII S (99) In infertile, anovulatory women, the initial treatment aimed at inducing ovulation usually involves the administration of an antiestrogen such as clomiphene citrate (CC). Although its precise mechanism of action remains largely unknown, the administration of CC is followed by an increase in the secretion of pituitary gonadotropins that results in follicular recruitment, the growth of one or more follicles, and ovulation (1). The use of CC is associated with ovulation rates of 70% 90% (2). This means that 10% 30% of patients do not respond to treatment with CC. Some of these nonresponding patients have elevated serum FSH, prolactin, or DHEAS levels (3). Patients with polycystic ovary syndrome (PCOS) or obesity appear to be resistant to CC therapy (4). Even nonobese women and women apparently free of other known endocrine abnormalities may be resistant to CC therapy. In most cases, the reason for this lack of response to CC stimulation is not known. Recent studies suggest a relation between GH and gonadal function. Human granulosa cells possess GH binding sites, and GH stimulates E 2 production in cultures of human granulosa cells (5). Menashe et al. (6) observed that the ovarian response to hmg stimulation is correlated with the GH response to clonidine stimulation. Ovesen et al. (7) demonstrated that anovulation and infertility are associated with an impaired secretory capacity for GH. Because there is no discrete evidence that CC activity is dependent on adequate GH se- 78
2 cretion, we designed the present study to assess whether the level of GH reserve is correlated with the ovulatory responsive to CC administration. MATERIALS AND METHODS Subjects Informed written consent was obtained before the study was initiated as part of an Institutional Review Board approved protocol. We recruited 33 women who had acyclic spontaneous bleeding and anovulatory infertility and were seeking ovulation induction. Their cycle length in the previous 6 months varied from days. Anovulation was diagnosed by basal body temperature and persistent low progesterone levels measured at 4- to 6-day intervals beginning on day 14 after the onset of bleeding. Endometrial biopsies performed at least 22 days after the last bleeding episode confirmed anovulation. Each subject underwent clinical and endocrinologic investigations, and her ovarian morphology was evaluated by ultrasonography. All patients had normal thyroid function and normal levels of LH, FSH, prolactin, testosterone, androstenedione, cortisol, and DHEAS as measured by conventional RIA. No patient had taken hormonal preparations for at least 3 months before the study. Women who had evidence of polycystic ovaries at ultrasound examination, hirsutism, hyperandrogenism, or an LH/FSH ratio of 2 were excluded. Nine women with a mean ( SD) age of years (range, years) and normal menstrual cycles served as controls. They all had regular menstrual cycles of days in length. Ovulation was confirmed in the controls by midluteal serum progesterone levels and basal body temperature graphs. All the women had normal ovaries on ultrasound examination. No woman in any of the three groups engaged in aerobic exercise during the study period. Study Design After an overnight fast, each woman received an oral dose of clonidine hydrochloride (0.3 mg, Catapresan; Boehringer, Reggello, Italy) on cycle days 5 7 after a spontaneous bleeding episode. All tests were begun between 8:30 A.M. and 9:00 A.M. and at least 30 minutes after the cannulation of a cubital vein, which was kept patent with a slow infusion of normal saline solution. Blood samples were drawn every 30 minutes starting 30 minutes before the administration of clonidine and continuing for 120 minutes thereafter. One week later, all women underwent an oral glucose tolerance test in which they received a 75-g glucose load after fasting for hours overnight. Blood was sampled at 0, 30, 60, 90, 120, and 180 minutes for determination of plasma glucose and serum insulin levels. Ovulation induction was started with 50 mg/d of CC administered from the fifth to the ninth days of the following cycle. The response was considered ovulatory when growth of a preovulatory follicle was observed by ultrasound, followed by a rise in serum progesterone levels in the midluteal phase. In patients who did not ovulate, the daily dose of CC was increased by 50 mg in each successive cycle up to a total daily dose of 250 mg. If no ovulation occurred, the patient was considered unresponsive to CC. Hormone Assays Insulin-like growth factor-i (IGF-I) was measured with a double-antibody RIA using immunochemicals and a tracer provided by Medgenix (Fleurus, Belgium). The sensitivity of the assay was 150 pg/ml; the intraassay and interassay coefficients of variation were 6% and 7.5%, respectively. Insulin-like growth factor binding protein-1 (IGFBP-1) was measured with an immunoradiometric assay using reagents and a tracer provided by Diagnostic Systems Laboratories, Inc. (Webster, TX). The sensitivity of the assay was 125 pg/ml; the intraassay and interassay coefficients of variation were 2.5% and 4.6%, respectively. Serum concentrations of the other hormones were determined using commercial RIA kits (Sorin, Saluggia, Italy). Intraassay and interassay coefficients of variation were 4.6% and 9.2% for GH, 5.3% and 6.7% for insulin, 5.8% and 7.4% for 17 -E 2, 5.5% and 9.3% for LH, 6.8 and 8.7% for FSH, 6.3% and 9.4% for testosterone, 6.1% and 9.3% for androstenedione, and 6.9% and 8.7% for sex hormone-binding globulin, respectively. Glucose levels were determined using the glucose oxidase technique. Statistical Analysis Each variable was expressed as the mean SD. The release of GH after clonidine administration and the responses of insulin and glucose to the glucose load were expressed as the area under the curve (AUC; calculated by the linear trapezoidal method). The data were analyzed by the Student s t test, the Mann- Whitney U test, analysis of variance for multiple comparisons, and Spearman s rank correlation coefficient. P.05 was considered statistically significant. RESULTS Based on their ovulatory response to CC, the patients were divided into two groups. Group 1 included 15 women who were not responsive to CC stimulation. The patients had a mean ( SD) age of years (range, years). Thirteen of the patients were of normal weight (body mass index [BMI], kg/m 2 ), 2 were overweight (BMI, kg/m 2 ), and none were obese (BMI, 29.5 kg/ m 2 ). The mean ( SD) BMI of the entire group was kg/m 2. Group 2 was composed of 18 patients who ovulated after the administration of CC. They had a mean ( SD) age of FERTILITY & STERILITY 79
3 TABLE 1 Clinical and endocrine characteristics of the anovulatory women and healthy controls. Variable Group 1 (CC-resistant) Group 2 (CC-responsive) Controls P value Age (y) NS BMI (kg/m 2 ) NS Cycle length (d) * GH level ( g/l) NS Glucose level (mmol/l) NS Insulin level (pmol/l) NS E 2 level (pmol/l) NS LH level (miu/ml) NS FSH level (miu/ml) NS Testosterone level (nmol/l) NS Androstenedione level (nmol/l) NS DHEAS level ( mol/l) NS SHBG level (nmol/l) NS Maximum insulin response (pmol/l) NS AUC for glucose (mmol/l 180 min) 1, , , NS AUC for insulin (pmol/l 180 min) 69,251 3,676 66,604 4,474 62,784 3,517 NS IGF-I (ng/ml) NS IGFBP-1 (ng/ml) NS Note: Values are means SD. NS not significant; SHBG sex hormone-binding globulin. * Group 1 vs. group 2 and the control group. Rossato. Growth hormone response. Fertil Steril years (range, years). Twelve of the women were of normal weight, 3 were overweight, and none were obese, according to the criteria outlined previously. The mean BMI of the entire group was kg/m 2. The cycle length during the last 6 months was significantly longer in group 1 (mean SD, days; range, days) than in group 2 (mean SD, days; range, days). The daily doses of CC required to induce ovulation were 50 mg in 4 women, 100 mg in 6 women, 150 mg in 4 women, 200 mg in 3 women, and 250 mg in 1 woman. In the control group, eight subjects were of normal weight and one was overweight. The mean ( SD) BMI of the entire group was kg/m 2. Table 1 shows the clinical and hormonal characteristics of the population studied. There were no differences in levels of gonadotropins, testosterone, androstenedione, or sex hormone-binding globulin between the study groups. Fasting glucose and insulin levels were similar in all three groups. The AUC for insulin and glucose in response to the oral administration of glucose was not significantly different between the groups. In patients who were not responsive to CC, levels of IGF-I were not different from those in patients who were responsive to CC, and they were not related to BMI. Concentrations of IGFBP-1 were normal in all patients. Determination of basal hormone levels showed that the women all had similar levels of E 2 ( pmol/l in group 1, pmol/l in group 2, and pmol/l in the control group). In addition, the mean ( SD) GH levels at 30 minutes and 0 minutes were not significantly different in the three groups ( g/l in group 1, g/l in group 2, and g/l in the control group). The administration of clonidine induced a significant increase in GH levels in all the groups studied (Fig. 1). The mean ( SD) peak GH level after the administration of clonidine was g/l in group 1, which was significantly lower than that in group 2 and in the control group (P.01). The mean ( SD) peak GH level was slightly, but not significantly, lower in group 2 than in the control group ( g/l vs g/l). The AUCs for GH are presented in Figure 2. After clonidine administration, there was a significant difference in the AUC for GH between group 1 and group 2 ( g/l vs g/l at 120 minutes, (P.01). There also was a statistically significant difference in the AUC for GH between group 1 and the control group ( g/l vs g/l at 180 minutes, P.01). There was no statistically significant difference when the AUC for GH was compared between group 2 and the control group. No significant correlation was observed between the GH response to clonidine and the dose of CC needed to induce ovulation (Spearman s rank correlation coefficient: r 0.421, P.116). The GH response to clonidine was not significantly correlated with the mean interval between bleeding episodes (Spearman s rank correlation coefficient: 80 Rossato et al. Secretion of GH in CC-resistant women Vol. 73, No. 1, January 2000
4 FIGURE 1 Growth hormone levels (mean SD) obtained after clonidine administration in two groups of infertile patients and a control group of healthy women with normal ovulation. *P.01, significantly different serum concentrations of GH in group 1 vs. group 2 and the control group. Rossato. Growth hormone response. Fertil Steril r 0.29, P.271 in group 1; and r 0.173, P.482 in group 2). No relevant side effects were observed after the administration of clonidine. A slight decrease in blood pressure was recorded in one patient in group 1, two patients in group 2, and no patients in the control group. No significant changes in heart rate were observed at any time during the study. DISCUSSION Anovulatory women who are resistant to CC therapy are a difficult problem for the clinician. Alternative therapy in these patients usually involves the administration of gonadotropins, which are expensive and associated with the risk of ovarian hyperstimulation syndrome and multiple pregnancy. Therefore, it is important to understand the reasons for resistance to CC so as to overcome them. Roozenburg et al. (8) treated a group of anovulatory subjects who were resistant to CC with naltrexone (an opioid receptor blocker) alone or in combination with an antiestrogen. Ovulation was achieved in 19 of 22 patients, demonstrating that endogenous opioids inhibit GnRH secretion and antagonize the effect of CC. An alternate explanation is that naltrexone reduces circulating insulin levels, thereby improving the ovarian response to gonadotropins. The reason for resistance to CC is not known in most patients, and the predominant sites and mechanisms of action of CC remain uncertain. Clomiphene citrate therapy in women results in elevated FSH and LH levels. However, these changes alone are not sufficient to explain the growth of ovarian follicles and ovulation that occur after treatment. It has been demonstrated that anovulatory patients who show a similar increase in gonadotropin levels after CC treatment have a very different rate of ovulation (9). Moreover, the variable growth of ovarian follicles exposed to comparable gonadotropic stimulation suggests that additional modulatory mechanisms play a role in the local control of follicular development. Evidence from human and in vitro studies suggests an important function for GH along with IGF-I and IGF-II in the regulation of folliculogenesis (10, 11). Our study demonstrated a decreased GH response to clonidine among women who were resistant to CC therapy compared with normal controls and women who were responsive to CC therapy. Clonidine generally is believed to be a specific FERTILITY & STERILITY 81
5 FIGURE 2 The GH response to clonidine as the AUC in two groups of infertile patients and in the control group. *P.01, significantly different AUC in group 1 vs. group 2 and the control group. Rossato. Growth hormone response. Fertil Steril activator of central 2 -adrenergic receptors, with no effect on serotonin or dopamine receptors, and it is used as a test of GH secretory reserve, particularly in children (12). Experimental research indicates that clonidine acts by increasing the secretion of hypothalamic GH-releasing hormone without altering somatostatin release (13). In our study, we excluded women with PCOS because a reduced GH response to levodopa and clonidine previously was demonstrated in patients with PCOS (14). Pyridostigmine significantly increased the GH response to levodopa in these women, demonstrating that reduced GH secretion in patients with PCOS may be associated with increased somatostatin activity. In the same study, Lee et al. (14) observed that IGF-I levels were significantly higher in women with PCOS than in controls. Elevated IGF-I levels may inhibit GH secretion through a negative feedback mechanism (15). Kazer et al. (16) observed normal plasma IGF-I concentrations and low GH levels in patients with PCOS. Women with PCOS frequently have insulin resistance and obesity. Insulin resistance is associated with hyperinsulinemia, and insulin can reduce GH secretion (16). Further, insulin-resistant women with PCOS also show resistance to CC (17). In our study, serum concentrations of IGF-I and IGFBP-1, fasting levels of insulin, and the response of insulin levels to the administration of a glucose load were similar in the anovulatory patients and the normal controls. The fact that insulin resistance does not underlie CC resistance in patients without PCOS is an important finding. Obesity is known to be associated with reduced GH levels (18). The BMI was comparable in the patients and controls in our study. Levels of E 2 can modify the secretion of GH in women. Word et al. (19) observed that an increased GH response to GH-releasing hormone is positively correlated with basal E 2 levels. However, in our study, E 2 levels were similar in CC-resistant and CC-responsive women, and not different from the levels observed in normal controls. These observations indicate that estrogen and body weight cannot explain the differences noted in the response of GH to clonidine. However, another study demonstrated a decreased GH response to arginine infusion in anovulatory women but did not distinguish CC-resistant and CC-responsive patients (8). Several studies indicate that GH plays a significant role in regulating the development and maturation of ovarian follicles by amplifying the effect of gonadotropins on ovarian follicular granulosa cells (20). It is known that 82 Rossato et al. Secretion of GH in CC-resistant women Vol. 73, No. 1, January 2000
6 menarche is delayed in GH-deficient subjects, and it was demonstrated that appropriate reproductive function can be restored by the administration of GH (21). Nevertheless, in Ecuadorian women with Laron-type dwarfism, a condition that is characterized by GH resistance, both the ovarian response to gonadotropin stimulation and fertility are normal (22). Thus, GH is important, but not critical, for follicular recruitment and development. Trials investigating the role of cotreatment with GH in the induction of ovulation have produced conflicting results. When it was given to ovulatory women who previously had been resistant to hmg, adjuvant GH treatment failed to improve follicular development and the ovarian response to gonadotropins. Suikkari et al. (23) observed that poor responders to GnRH agonists and gonadotropins do not benefit from cotreatment with human GH during ovarian stimulation. More favorable results were obtained by administering GH to anovulatory women. Homburg et al. (24) observed that GH administered in a placebo-controlled fashion decreased the required dose of hmg in hypogonadotropic patients. The addition of GH to hmg significantly increased the pregnancy rate in clonidinenegative, but not clonidine-positive, infertile women (25). Patients with PCOS who underwent IVF showed a significantly improved response to hmg when pharmacologic doses of GH were added to their superovulation protocols (26). In our study, there was a statistically significant difference in mean cycle length between groups 1 and 2, with a longer mean interval between bleeding episodes in CCresistant women. Genazzani et al. (27) reported that the administration of GH significantly increased integrated LH plasma levels and the LH pulse frequency and amplitude in normogonadotropinemic amenorrheic patients. Therefore, endogenous GH may act on the gonadotropes and modulate LH responsiveness to GnRH. It can be hypothesized that reduced endogenous GH secretion also may impair the function of the hypothalamicgonadotropic-pituitary axis. In group 1, reduced GH secretory reserve was associated with a defect in the hypothalamic regulation of gonadotropin release. A direct effect of GH on granulosa cells has been demonstrated, although the exact role of GH in follicular growth remains to be clarified. Therefore, another explanation is that the reduced GH response to clonidine and the longer cycle length are related to an improper ovarian response to gonadotropins. Our study showed that anovulatory patients who are resistant to CC therapy have a hypothalamic-pituitary disorder and a relative GH deficiency that may result from increased somatostatinergic tone. Although CC-responsive and CCresistant women had similar basal GH levels, it seems that an adequate secretory capacity for GH is important for CC action. However, further studies are necessary to establish whether basal secretion of GH also is impaired and whether the additional administration of GH might transform CCresistant anovulatory women without hyperandrogenism or polycystic ovaries into CC-responsive women. References 1. Downs KA, Gibson M. Clomiphene citrate therapy for luteal phase defect. Fertil Steril 1983;39: Hammond MG. Monitoring technique for improved pregnancy rates during clomiphene ovulation induction. Fertil Steril 1984;42: Lobo RA, Gysler M, March CM, Goebelsmann M, Mishell DR. Clinical and laboratory predictors of clomiphene response. Fertil Steril 1982;37: Isaacs JD, Lincoln SR, Cowan BD. Extended clomiphene citrate (CC) and prednisone for the treatment of chronic anovulation resistant to CC alone. Fertil Steril 1997;67: Barreca A, Artini PG, Del Monte P, Ponzani P, Pasquini P, Cariola G, et al. In vivo and in vitro effect of growth hormone on estradiol secretion by human granulosa cells. J Clin Endocrinol Metab 1993;77: Menashe Y, Lunenfeld B, Pariente C, Frenkel Y, Mashiach S. Can growth hormone increase, after clonidine administration, predict the dose of human menopausal hormone needed for induction of ovulation? Fertil Steril 1990;53: Ovesen P, Moller G, Moller N, Christiansen JS, Orskov JOL. Growth hormone secretory capacity and serum insulin-like growth factor I levels in primary infertile, anovulatory women with regular menses. Fertil Steril 1992;57: Roozenburg BJ, van Dessel H, Evers J, Bots R. Successful induction of ovulation in normogonadotrophic clomiphene resistant anovulatory women by combined naltrexone and clomiphene citrate treatment. Hum Reprod 1997;12: Quigley MM, Berkowitz AS, Gilbert SA, Wolf DP. Clomiphene citrate in an in vitro fertilization program: hormonal comparisons between 50- and 150-mg daily dosages. Fertil Steril 1984;41: Adashi E. Intraovarian regulation: the proposed role of insulin-like growth factors. Ann NY Acad Sci 1993;697: Barreca A, Del Monte P, Ponzani P, Artini PG, Genazzani AR, Minuto F. Intrafollicular insulin-like growth factor-ii levels in normally ovulating women and in patients with polycystic ovary syndrome. Fertil Steril 1996;65: Saggese G, Cesaretti G, Giannesi N, Brancaloni C, Cinquanta L, Cioni C. Stimulated growth hormone (GH) secretion in children with delays of pubertal development before and after the onset of puberty: relationship with peripheral plasma GH-releasing hormone and somatostatin levels. J Clin Endocrinol Metab 1992;74: Magnan E, Catldi M, Guillaume V. Role of growth hormone (GH)- releasing hormone and somatostatin in the mediation of clonidine induced GH release in sheep. Endocrinology 1994;134: Lee E-J, Lee BS, Lee HC, Park KH, Song CH, Huh KB. Growth hormone response to L-dopa and pyridostigmine in women with polycystic ovarian syndrome. Fertil Steril 1993;60: Yamashita S, Weiss M, Melmed S. Insulin-like growth factor I regulates growth hormone secretion and messenger ribonucleic acid levels in human pituitary tumour cells. J Clin Endocrinol Metab 1986;63: Kazer RR, Unterman TG, Glick RP. An abnormality of the growth hormone/insulin-like growth factor-i axis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1990;71: Murakawa H, Hasegawa I, Kurabayashi T, Tanaka K. Polycystic ovary syndrome. Insulin resistance and ovulatory response to clomiphene citrate. J Reprod Med 1999;44: Slowinska-Srdeznicka J, Zgliczynsksi W, Wakowska A, Jeske W, Brzezinska A, Soszynski P, et al. An abnormality of the growth hormone/insulin like growth factor-i axis in women with polycystic ovary syndrome due to coexistent obesity. J Clin Endocrinol Metab 1992;74: Word RA, Odom MJ, Byrd W, Carr BR. The effect of gonadotropinreleasing hormone agonists on growth hormone secretion in adult premenopausal women. Fertil Steril 1990;54: Ovesen P, Ingerslev HJ, Orskov H, Ledet T. Effect of growth hormone on steroidogenesis, insulin-like growth factor-1 (IGF-1) and IGF-binding protein-1 production and DNA synthesis in cultured human luteinized granulosa cells. J Endocrinol 1994;140: Katz E, Ricciarelli E, Adashi EY. The potential relevance of growth hormone to female reproductive physiology and pathophysiology. Fertil Steril 1993;59: Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J. Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr Rev 1994;15: Suikkari A-M, MacLachlan V, Koistinen R, Seppâlä M, Healy DL. Double-blind placebo controlled study: human biosynthetic growth hormone for assisted reproductive technology. Fertil Steril 1996;65: FERTILITY & STERILITY 83
7 24. Homburg R, Levy T, Ben-Rafael Z. Adjuvant growth hormone for induction of ovulation with gonadotrophin-releasing hormone agonist and gonadotrophins in polycystic ovary syndrome: a randomized double blind placebo controlled trial. Hum Reprod 1995;10: Blumenfeld Z, Dirnfeld M, Gonen Y, Abramovici H. Growth hormone co-treatment for ovulation induction may enhance conception in the co-treatment and succeeding cycles, in clonidine negative but not clonidine positive patients. Hum Reprod 1994;9: Volpe A, Artini PG, Barreca A, Coukos G, Minuto F, Genazzani AR. Effects of growth hormone administration in addition to gonadotrophins in normally ovulating women and polycystic ovary syndrome (PCO) patients. Hum Reprod 1992;7: Genazzani AD, Petraglia F, Volponi C. Growth hormone treatment affects plasma LH pulsatile release in women with secondary amenorrhoea. Clin Endocrinol (Oxf) 1993;39: Rossato et al. Secretion of GH in CC-resistant women Vol. 73, No. 1, January 2000
Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance related polycystic ovary syndrome
FERTILITY AND STERILITY VOL. 71, NO. 2, FEBRUARY 1999 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Effect of troglitazone
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome Definition: the diagnostic criteria Evidence of hyperandrogenism, biochemical &/or clinical (hirsutism, acne & male pattern baldness). Ovulatory dysfunction; amenorrhoea; oligomenorrhoea
More informationROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)
ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU) In 1935, Stein and Leventhal described 7 women with bilateral enlarged PCO, amenorrhea or irregular menses, infertility and masculinizing
More informationclinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome
& clinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome Zulfo Godinjak¹*, Ranka Javorić² 1 Gynecology and Obstetrics
More informationGH IS DIRECTLY, or indirectly through the insulin-like
0021-972X/99/$03.00/0 Vol. 84, No. 2 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1999 by The Endocrine Society Growth Hormone (GH) Substitution in Hypogonadotropic, GH-Deficient
More informationAchieving Pregnancy: Obesity and Infertility. Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center
Achieving Pregnancy: Obesity and Infertility Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center Disclosures Speakers Bureau EMD Serono Board of Directors Nurse
More informationCASE 41. What is the pathophysiologic cause of her amenorrhea? Which cells in the ovary secrete estrogen?
CASE 41 A 19-year-old woman presents to her gynecologist with complaints of not having had a period for 6 months. She reports having normal periods since menarche at age 12. She denies sexual activity,
More informationInfertility for the Primary Care Provider
Infertility for the Primary Care Provider David A. Forstein, DO FACOOG Clinical Associate Professor Obstetrics and Gynecology University of South Carolina School of Medicine Greenville Disclosure I have
More informationApproach to ovulation induction and superovulation in women with a history of infertility. Anatte E. Karmon, MD
Approach to ovulation induction and superovulation in women with a history of infertility Anatte E. Karmon, MD Disclosures- Anatte Karmon, MD No financial relationships to disclose 2 Objectives At the
More informationPolycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018
Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018 Learning Objectives At the conclusion of this lecture, learners should: 1) Know the various diagnostic
More informationGonadotrophin treatment in patients with Polycystic Ovary Syndrome
Int. J. Adv. Res. Biol. Sci. (218). 5(4): 95-99 International Journal of Advanced Research in Biological Sciences ISSN: 2348-869 www.ijarbs.com DOI: 1.22192/ijarbs Coden: IJARQG(USA) Volume 5, Issue 4-218
More informationPolycystic Ovarian Syndrome (PCOS) LOGO
Polycystic Ovarian Syndrome (PCOS) Ma qianhong Ob/Gyn Department LOGO Contents Epidemiology and Definition Pathophysiology, Endocrinological Features Diagnostic Criteria Treatment Prognosis Introduction
More informationDaily blood hormone levels related to the luteinizing hormone surge in anovulatory cycles
FRTILITY AND STRILITY Copyright 1983 The American Fertility Society Printed in U.8A. Daily blood hormone levels related to the luteinizing hormone surge in anovulatory cycles Chung H. Wu, M.D. * F. Susan
More informationFemale Reproductive Endocrinology
Female Reproductive Endocrinology Dr. Channa Jayasena PhD MRCP FRCPath Clinical Senior Lecturer & Consultant Endocrinologist Department of Gynaecology, Hammersmith Hospital Anovulation is a common cause
More informationEndocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound
Human Reproduction vol.12 no.5 pp. 905 909, 1997 Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound E.Carmina 1, L.Wong 2, L.Chang 2, R.J.Paulson 2, disturbance of the IGF/IGFBP-l
More informationwww.iffs-reproduction.org @IntFertilitySoc Int@FedFertilitySoc Conflict of interest none Outline Causes of ovulatory dysfunction Assessment of women with ovulatory dysfunction Management First line Second
More informationUnderstanding Infertility, Evaluations, and Treatment Options
Understanding Infertility, Evaluations, and Treatment Options Arlene J. Morales, M.D., F.A.C.O.G. Fertility Specialists Medical Group, Inc. What We Will Cover Introduction What is infertility? Briefly
More informationReproductive Health and Pituitary Disease
Reproductive Health and Pituitary Disease Janet F. McLaren, MD Assistant Professor Division of Reproductive Endocrinology and Infertility Department of Obstetrics and Gynecology jmclaren@uabmc.edu Objectives
More informationInvestigation of adrenal functions in patients with idiopathic hyperandrogenemia
European Journal of Endocrinology (26) 155 37 311 ISSN 84-4643 CLINICAL STUDY Investigation of adrenal functions in patients with idiopathic hyperandrogenemia Hulusi Atmaca, Fatih Tanriverdi 1, Kursad
More informationOverview of Reproductive Endocrinology
Overview of Reproductive Endocrinology I have no conflicts of interest to report. Maria Yialamas, MD Female Hypothalamic--Gonadal Axis 15 4 Hormone Secretion in the Normal Menstrual Cycle LH FSH E2, Progesterone,
More informationReproductive FSH. Analyte Information
Reproductive FSH Analyte Information 1 Follicle-stimulating hormone Introduction Follicle-stimulating hormone (FSH, also known as follitropin) is a glycoprotein hormone secreted by the anterior pituitary
More informationNeil Goodman, MD, FACE
Initial Workup of Infertile Couple: Female Neil Goodman, MD, FACE Professor of Medicine Voluntary Faculty University of Miami Miller School of Medicine Scope of Infertility in the United States Affects
More informationCommon protocols in intra-uterine insemination cycles
Common protocols in intra-uterine insemination cycles Doç. Dr. Candan İltemir Duvan Turgut Özal Üniversitesi Tıp Fakültesi Kadın Hastalıkları ve Doğum AD Ovulation induction with intra-uterine insemination
More informationNature and Science 2017;15(8)
Prognostic Value of Day 3 Luteinising Hormone (LH) in the prediction of Ovarian Response in Patients with Polycystic Ovary syndrome Mohammed Samir Fouad 1 ; Mohammed Said El-Shorbagy 2, Mohammed Mohammed
More informationIVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn)
34 11 Vol.34 No.11 2014 11 Nov. 2014 Reproduction & Contraception doi: 10.7669/j.issn.0253-3X.2014.11.0892 E-mail: randc_journal@163.com IVF ( 710003) : (H-hMG) - (IVF- ET) : GnRH H-hMG (H-hMG ) (rfsh
More informationCase Questions. Polycystic Ovarian Syndrome: Treatment Goals and Options. Differential Diagnosis of Hyperandrogenic Anovulation
Polycystic Ovarian Syndrome: Treatment Goals and Options Marc Cornier, MD Division of Endocrinology, Metabolism and Diabetes Colorado Center for Health and Wellness University of Colorado School of Medicine
More informationNorth Carolina Center for Reproductive Medicine, Cary, North Carolina
FERTILITY AND STERILITY VOL. 75, NO. 3, MARCH 2001 Copyright 2001 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Metformin treatment
More informationPolycystic Ovary Syndrome
What is the polycystic ovary syndrome? Polycystic Ovary Syndrome The polycystic ovary syndrome (PCOS) is a clinical diagnosis characterized by the presence of two or more of the following features: irregular
More informationInfertility: failure to conceive within one year of unprotected regular sexual intercourse. Primary secondary
Subfertility Infertility: failure to conceive within one year of unprotected regular sexual intercourse. Primary secondary Infertility affects about 15 % of couples. age of the female. Other factors that
More informationReproductive outcome in women with body weight disturbances
Reproductive outcome in women with body weight disturbances Zeev Shoham M.D. Dep. Of OB/GYN Kaplan Hospital, Rehovot, Israel Weight Status BMI (kg/m 2 ) Underweight
More informationNew PCOS guidelines: What s relevant to general practice
New PCOS guidelines: What s relevant to general practice Dr Michael Costello Fertility Specialist IVF Australia UNSW Royal Hospital for Women Sydney How do we know if something is new? Louvre Museum, Paris
More informationDoes previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles?
J Assist Reprod Genet (26) 23:427 431 DOI 1.17/s1815-6-965-x ASSISTED REPRODUCTION Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation
More informationDepartment of Obstetrics and Gynecology, University of Modena, Modena, Italy
FERTILITY AND STERILITY VOL. 81, NO. 1, JANUARY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Metformin administration modulates
More informationPCOS and Obesity DUB is better treated by OCPs
PCOS and Obesity DUB is better treated by OCPs Dr. Ritu Joshi Senior consultant Fortis escorts Hospital, Jaipur Chairperson Family welfare com. FOGSI (20092012) Vice President FOGSI 2014 Introduction One
More informationEndocrinology of the Female Reproductive Axis
Endocrinology of the Female Reproductive Axis girlontheriver.com Geralyn Lambert-Messerlian, PhD, FACB Professor Women and Infants Hospital Alpert Medical School at Brown University Women & Infants BROWN
More informationOvarian sensitivity to follicle stimulating hormone is blunted in normo-ovulatory women with Down s syndrome
Human Reproduction vol.12 no.8 pp.1709 1713, 1997 Ovarian sensitivity to follicle stimulating hormone is blunted in normo-ovulatory women with Down s syndrome Rosa Maria Cento, Letizia Ragusa, Caterina
More informationReproductive physiology
Reproductive physiology Sex hormones: Androgens Estrogens Gestagens Learning objectives 86 (also 90) Sex Genetic sex Gonadal sex Phenotypic sex XY - XX chromosomes testes - ovaries external features Tha
More informationDOES INSULIN RESISTANCE CAUSE HYPERANDROGENEMIA OR HYPERANDROGENEMIA CAUSES INSULIN RESISTANCE IN PCOS
DOES INSULIN RESISTANCE CAUSE HYPERANDROGENEMIA OR HYPERANDROGENEMIA CAUSES INSULIN RESISTANCE IN PCOS D R. G A N A P A T H I. B D E P T. O F E N D O C R I N O L O G Y S T. J O H N S M E D I C A L C O
More informationAcute insulin response to intravenous glucagon in polycystic ovary syndrome
Human Reproduction vol.13 no.4 pp.847 851, 1998 Acute insulin response to intravenous glucagon in polycystic ovary syndrome Mario Ciampelli 1, Anna M.Fulghesu 1, Francesca Murgia 1, Maurizio Guido 1, Francesco
More informationN. Shirazian, MD. Endocrinologist
N. Shirazian, MD Internist, Endocrinologist Inside the ovary Day 15-28: empty pyfollicle turns into corpus luteum (yellow body) Immature eggs Day 1-13: 13: egg developing inside the growing follicle Day
More informationCan Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome?
www.ijpm.in www.ijpm.ir Can Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome? Ferdous Mehrabian, Maryam Afghahi Department
More informationNitasha Garg 1 Harkiran Kaur Khaira. About the Author
https://doi.org/10.1007/s13224-017-1082-4 ORIGINAL ARTICLE A Comparative Study on Quantitative Assessment of Blood Flow and Vascularization in Polycystic Ovary Syndrome Patients and Normal Women Using
More informationInfertility Treatment in Polycystic Ovary Syndrome: Lifestyle Interventions, Medications and Surgery
Macut D, Pfeifer M, Yildiz BO, Diamanti-Kandarakis E (eds): Polycystic Ovary Syndrome. Novel Insights into Causes Infertility Treatment in Polycystic Ovary Syndrome: Lifestyle Interventions, Medications
More informationSummary
Summary 118 This thesis is focused on the background of elevated levels of FSH in the early follicular phase of women with regular menstrual cycles. In the introduction (chapter 1) we describe the characteristics
More informationClinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes
POLYCYSTIC OVARY SYNDROME Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes Ettore Guastella, M.D., a Rosa Alba Longo, M.D., b and Enrico Carmina, M.D. b a Department
More informationMetformin in early pregnancy and abortions. Laure Morin-Papunen, MD, PhD Dept. of Obstetrics and Gynecology University Hospital of Oulu, Finland
Metformin in early pregnancy and abortions Laure Morin-Papunen, MD, PhD Dept. of Obstetrics and Gynecology University Hospital of Oulu, Finland PCOS and miscarriage risk Metformin and miscarriage risk
More informationDr Stella Milsom. Endocrinologist Fertility Associates Auckland. 12:30-12:40 When Puberty is PCO
Dr Stella Milsom Endocrinologist Fertility Associates Auckland 12:30-12:40 When Puberty is PCO Puberty or Polycystic Ovary Syndrome? Stella Milsom Endocrinologist Auckland DHB, University of Auckland,
More informationINSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME An Overview
INSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME An Overview University of PNG School of Medicine & Health Sciences Division of Basic Medical Sciences PBL MBBS III VJ Temple 1 Insulin Resistance: What is
More informationMetformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome
IJMS Vol 36, No 2, June 2011 Original Article Metformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome Marzieh Farimani Sanoee 1, Nosrat Neghab 1, Soghra
More informationPolycystic Ovary Syndrome (PCOS):
Polycystic Ovary Syndrome (PCOS): Current diagnosis and treatment Anatte E. Karmon, MD Disclosures- Anatte Karmon, MD No financial relationships to disclose 2 Objectives At the end of this presentation,
More informationClinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients
International Reproductive Medicine Volume 2013, Article ID 135258, 4 pages http://dx.doi.org/10.1155/2013/135258 Clinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin
More informationGonadotropin-releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovarian syndrome
FERTILITY AND STERILITY Copyright e 1993 The American Fertility Society Vol. 59, No.3, March 1993 Printed on acid-free paper in U.S.A. Gonadotropin-releasing hormone agonist reduces the miscarriage rate
More informationAbstract. Introduction. RBMOnline - Vol 10. No Reproductive BioMedicine Online; on web 15 November 2004
RBMOnline - Vol 10. No 1. 2005 100-104 Reproductive BioMedicine Online; www.rbmonline.com/article/1484 on web 15 November 2004 Article Metformin monotherapy in lean women with polycystic ovary syndrome
More informationPolycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks
Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Human Ovarian Steroidogenesis and Gonadotrophin Stimulation Johan
More informationlbt lab tests t Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour
lbt lab tests t and Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour Research Instituteof Avicenna 4/23/2012 Why good prediction of poor response good prediction i of OHSS application appropriate
More informationFemale Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF
Female Reproductive Physiology Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF REFERENCE Lew, R, Natural History of ovarian function including assessment of ovarian reserve
More informationIn Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome
Original Article Effect of Laparoscopic Ovarian Drilling on Outcomes of In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome Maryam Eftekhar, M.D. 1, Razieh Deghani Firoozabadi,
More informationOriginal Article. Fauzia HaqNawaz 1*, Saadia Virk 2, Tasleem Qadir 3, Saadia Imam 3, Javed Rizvi 2
Original Article Comparison of Letrozole and Clomiphene Citrate Efficacy along with Gonadotrophins in Controlled Ovarian Hyperstimulation for Intrauterine Insemination Cycles Fauzia HaqNawaz 1*, Saadia
More informationThe contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome
Human Reproduction vol.14 no.2 pp.307 311, 1999 The contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome E.Carmina 1, F.Gonzalez 2, A.Vidali
More informationReproductive Testing: Less is More G. Wright Bates, Jr., M.D. Professor and Director Reproductive Endocrinology and Infertility Objectives
Reproductive Testing: Less is More G. Wright Bates, Jr., M.D. Professor and Director Reproductive Endocrinology and Infertility Objectives 1. Review definition of infertility and impact of age 2. Stress
More informationHormone Balance - Female Report SAMPLE. result graph based on Luteal Phase. result graph based on Luteal Phase
Patient Name: Patient DOB: Gender: Physician: Test Hormone Balance - Female Report SAMPLE Grote, Mary Jane Batch Number: B6437 2/16/1954 Accession Number: N52281 F Date Received: 2/3/2015 Any Lab Test
More informationRisk factors for spontaneous abortion in menotropintreated
FERTILITY AND STERILITY Copyright ~ 1987 The American Fertility Society Vol. 48, No. 4, October 1987 Printed in U.S.A. Risk factors for spontaneous abortion in menotropintreated women Michael Bohrer, M.D.*
More informationDepartment of Obstetrics and Gynecology, Changhua Christian Hospital, Institute of Medical Research, Chang Jung University, Changhua 500, Taiwan
Endocrine Journal 2005, 52 (4), 407 412 Relationship between Sex Hormone-Binding Globulin and Pregnancy Outcome in Women Undergoing Controlled Ovarian Hyperstimulation for Assisted Reproduction KUO-CHERNG
More informationLeptin concentrations in the follicular phase of spontaneous cycles and cycles superovulated with follicle stimulating hormone
Human Reproduction vol.13 no.5 pp.1152 1156, 1998 Leptin concentrations in the follicular phase of spontaneous cycles and cycles superovulated with follicle stimulating hormone I.E.Messinis 1,4, S.Milingos
More informationValidation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome
Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D., a Bart C. J. M. Fauser, M.D., Ph.D., b Joop S. E. Laven,
More informationCurrent and future status of ovulation induction in polycystic ovary syndrome
Human Reproduction Update 1997, Vol. 3, No. 3 pp. 235 253 European Society for Human Reproduction and Embryology Current and future status of ovulation induction in polycystic ovary syndrome Ioannis E.Messinis
More information12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman
Polycystic Ovarian Syndrome (PCOS) for the Family Physician Barbara S. Apgar MD, MS Professor or Family Medicine University of Michigan Ann Arbor, Michigan Important references for PCOS Endocrine Society
More informationPolycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks. Kate D. Schoyer, M.D. May 6, 2016
Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)
More informationEndocrine control of female reproductive function
Medicine School of Women s & Children s Health Discipline of Obstetrics & Gynaecology Endocrine control of female reproductive function Kirsty Walters, PhD Fertility Research Centre, School of Women s
More informationLuteal phase rescue after GnRHa triggering Progesterone and Estradiol
Luteal phase rescue after GnRHa triggering Progesterone and Estradiol L. Engmann University of Connecticut Disclaimer Fertility Speaker Bureau Merck Pharmaceuticals Introduction GnRH agonist is effective
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/24875
More informationAmenorrhoea: polycystic ovary syndrome
There is so much we don't know in medicine that could make a difference, and often we focus on the big things, and the little things get forgotten. To highlight some smaller but important issues, we've
More informationGONADAL FUNCTION: An Overview
GONADAL FUNCTION: An Overview University of PNG School of Medicine & Health Sciences Division of Basic Medical Sciences Clinical Biochemistry BMLS III & BDS IV VJ Temple 1 What are the Steroid hormones?
More informationJournal of American Science 2013;9(12) Mohamed Elkadi, Amr Elhelaly, Ahmed Ibrahim, Shereen Abdelaziz
Clomiphene Citrate Alone or Followed by Human Chorionic Gonadotropin In Induction of Ovulation. Mohamed Elkadi, Amr Elhelaly, Ahmed Ibrahim, Shereen Abdelaziz Department of Obstetrics and Gynecology Ain
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal myomectomy in leiomyoma management, 77 Abnormal uterine bleeding (AUB) described, 103 105 normal menstrual bleeding vs., 104
More informationMetformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice
Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice N. D. C. Sturrock, 1 B. Lannon 2 & T. N. Fay 2 Departments of 1 Endocrinology and 2
More informationS. AMH in PCOS Research Insights beyond a Diagnostic Marker
S. AMH in PCOS Research Insights beyond a Diagnostic Marker Dr. Anushree D. Patil, MD. DGO Scientist - D National Institute for Research in Reproductive Health (Indian Council of Medical Research) (Dr.
More informationTest Briefing on Hormonal Disorders and Infertility
Test Briefing on Hormonal Disorders and Infertility Test Briefing on Hormonal Disorders Common Tests FSH LH Progesterone Estradiol Prolactin Testosterone AFP AMH PCOS Panel FSH (Follicle Stimulating Hormone)
More informationThe importance of human chorionic gonadotropin support of the corpus luteum during human gonadotropin therapy in women with anovulatory infertility
FERTILITY AND STERILITY Copyright 0 1988 The American Fertility Society Printed in U.S.A. The importance of human chorionic gonadotropin support of the corpus luteum during human gonadotropin therapy in
More informationReproductive Hormones
Reproductive Hormones Male gonads: testes produce male sex cells! sperm Female gonads: ovaries produce female sex cells! ovum The union of male and female sex cells during fertilization produces a zygote
More informationDr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain. Declared no potential conflict of interest
Dr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain Declared no potential conflict of interest Is there a role for LH in elderly patients? Dr. Ernesto Bosch Instituto Valenciano de Infertilidad.
More informationInfertility: A Generalist s Perspective
Infertility: A Generalist s Perspective Learning Objectives Fertility and Lifestyle: Patient education Describe the basic infertility workup Basic treatment strategies unexplained Heather Huddleston, MD
More informationJessicah S. Collins, Jennifer P. Beller, Christine Burt Solorzano, James T. Patrie, R. Jeffrey Chang, John C. Marshall, Christopher R.
Supplemental Materials for manuscript entitled Blunted Day-Night Changes in Luteinizing Hormone Pulse Frequency in Girls with Obesity: the Potential Role of Hyperandrogenemia Jessicah S. Collins, Jennifer
More informationBulent Urman, M.D.* Margo R. Fluker, M.D. Basil Ho Yuen, M.B., Ch.B.t
FERTILITY AND STERILITY Copyright c 1992 The American Fertility Society Vol. 57, No.6, June 1992 Printed on acid-free paper in U.S.A. The outcome of in vitro fertilization and embryo transfer in women
More informationAromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders
FERTILITY AND STERILITY VOL. 77, NO. 4, APRIL 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Aromatase inhibition
More informationThe role of changing pulse frequency in the regulation of ovulation
Human Reproduction vol.8 Suppl.2 pp.57-61, 1993 The role of changing pulse frequency in the regulation of ovulation J.C.Marshall 1 and M.L.Griffin Division of Endocrinology and Metabolism, Department of
More informationReproduction. AMH Anti-Müllerian Hormone. Analyte Information
Reproduction AMH Anti-Müllerian Hormone Analyte Information - 1-2011-01-11 AMH Anti-Müllerian Hormone Introduction Anti-Müllerian Hormone (AMH) is a glycoprotein dimer composed of two 72 kda monomers 1.
More informationThe Pharmacology of PCOS
The Pharmacology of PCOS G. Wright Bates, Jr., M.D. Director Reproductive Endocrinology & Infertility University of Alabama at Birmingham Objectives Review the diagnosis of PCOS Highlight lifestyle modifications
More informationSerum Vascular Endothelial Growth Factor in Polycystic Ovary Syndrome and its Relation to Ovarian Drilling
Available online on www.ijtpr.com International Journal of Toxicological and Pharmacological Research 2014; 6(4): 123-127 Research Article ISSN: 0975-5160 Serum Vascular Endothelial Growth Factor in Polycystic
More informationObjectives 06/21/18 STILL A PLACE FOR PILLS DON T IVF EVERYTHING. Clomiphene citrate and Letrozole. Infertility Case Studies. Unexplained Infertility
STILL A PLACE FOR PILLS DON T IVF EVERYTHING Jeff Roberts M.D. Co-Director, Pacific Centre for Reproductive Medicine Objectives 1 2 3 4 5 Clomiphene citrate and Letrozole Infertility Case Studies Unexplained
More informationRichard S. Legro, M.D., Penn State College of Medicine, Dept of Ob/Gyn, Hershey, PA, USA
What have we learned from Multi-Clinical Trials in PCOS: Focus on Infertility Richard S. Legro, M.D., Penn State College of Medicine, Dept of Ob/Gyn, Hershey, PA, USA Disclosures Consultant: Euroscreen,
More informationMODULE 1: OVULATION INDUCTION IN NORMAL RESPONDERS, POOR RESPONDERS, AND HYPERRESPONDERS
MODULE 1: OVULATION INDUCTION IN NORMAL RESPONDERS, POOR RESPONDERS, AND HYPERRESPONDERS Contents OVULATION INDUCTION IN NORMAL RESPONDERS, POOR RESPONDERS, AND HYPERRESPONDERS Ovulation Induction.....................................................................
More informationUterus & Ovary 2015; 2: e904. doi: /uo.904; 2015 by Ahmed M Maged, et al.
RESEARCH ARTICLE Phytoestrogens as an alternative to estradiol in reversing the antiestrogenic effect of clomid on endometrium in ovulation induction in cases of polycystic ovarian syndrome (PCOS) Ahmed
More informationInfertility. Review and Update Clifford C. Hayslip MD Intrauterine Inseminations
Infertility Review and Update Clifford C. Hayslip MD Intrauterine Inseminations Beneficial effects of IUI not consistently documented in studies No deleterious effects on fertility 3-4 cycles of IUI should
More informationHormonal Control of Human Reproduction
Hormonal Control of Human Reproduction Bởi: OpenStaxCollege The human male and female reproductive cycles are controlled by the interaction of hormones from the hypothalamus and anterior pituitary with
More informationUltrasound of Uterus and Ovary
1 of 16 5/3/2005 8:34 PM Contents: Ultrasound of Uterus and Ovary Introduction Section 1: The Normal Ovary by Ultrasound Section 2: Ultrasound of Normal Ovarian Follicular Cycles Section 3: Ultrasound
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article A Study on Assessment of Testosterone, Insulin Resistance and HbA1c in Women with Polycystic
More informationPERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW.
PERIMENOPAUSE Patricia J. Sulak, MD Founder, Living WELL Aware LLC Author, Should I Fire My Doctor? Author, Living WELL Aware: Eleven Essential Elements to Health and Happiness Endowed Professor Texas
More informationInstitute of Obstetrics and Gynecology, Universitii Cattolica del Sacro Cuore, Rome, and Oasi Institute of Research, Troina, Italy
FERTILITY AND STERILI'fY Copyright < 1996 American Society for Reproductive Medicine Printed on acid free paper in U. S. A. Insulin-like growth factor (IGF)-I and IGF-II stimulate progesterone production
More information